Navigation Links
Xanodyne Pharmaceuticals Appoints New Chief Operating Officer
Date:5/17/2011

NEWPORT, Ky. and MOUNT ARLINGTON, N.J., May 17, 2011 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., is pleased to announce that Fabrice Egros has been appointed to the position of Chief Operating Officer reporting to Natasha Giordano, President and Chief Executive Officer.

Fabrice Egros has more than 20 years of experience in the pharmaceutical industry and prior to Xanodyne served in various senior positions in UCB Pharmaceuticals (Belgium, US and Japan).  His depth of experience includes senior leadership positions in general management, corporate business development, clinical development & regulatory as well as marketing and sales in Europe, Asia and the US at major pharmaceutical companies including Sanofi-Aventis and Parke-Davis.

Mr. Egros said, "I look forward to working with Natasha and the management team in continuing to drive toward our vision of being a leader in the pain management category.  Xanodyne has a proven track record of bringing innovative products to the market and developing strategic partnerships where desired, as well as the people, resources and strategy to focus Xanodyne on high growth opportunities within the pain franchise."  

Ms. Giordano said, "I am very pleased to welcome Fabrice to our management team.  His global knowledge of the industry, deep experience in corporate development and his strong leadership will help us achieve our strategic goals and commercial success in pain management."

About Xanodyne Pharmaceuticals, Inc.

Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on pain management. Xanodyne markets a portfolio of prescription pharmaceuticals and a line of prenatal vitamins.  Additionally, we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus area.  For more information, visit www.Xanodyne.com.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xanodyne Agrees to Withdraw Propoxyphene From the U.S. Market
2. Xanodyne Announces Planned President & CEO Succession
3. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
4. Xanodyne Announces Renewed Focus on Pain Management Market
5. Xanodyne Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules
6. Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
7. Access Pharmaceuticals Provides Update on MuGard Commercial Activities
8. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
9. Amylin Pharmaceuticals Files Suit Against Eli Lilly
10. Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
11. Reportlinker Adds Pharmaceuticals Reports Bundle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology:
(Date:4/28/2017)... Olathe, KS (PRWEB) , ... April 28, 2017 ... ... system have typically been previously exposed to more adverse experiences than children in ... have experienced trauma such as abuse, neglect or other family challenges. While no ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... the Creator responds to and which He does not. Yisrayl says with so many ... is the true name, but he says with a little Scripture, backed with a lot ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
Breaking Medicine News(10 mins):